ADIAL PHARMACEUTICALS, INC.
No SEC Form 4 filings for $ADIL in the last 30 days.
See all $ADIL insider activity →ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001513525 0001513525 2026-08-17 2026-08-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001513525 0001513525 2026-08-10 2026-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Investing.com reported U.S. insider trading for July 16, 2026. Major buys included Boundless Bio (63,969 shares, about $155.6k), ADIAL Pharmaceuticals (3,233 shares, $8,690), FIS (1,386 shares, $57.4k) and Cardiff Oncology (34,364 shares plus warrants). Major sells included Celcuity (3.1M shares, about $317.8M), Arista Networks (300k shares, about $54.2M), Butterfly Network (4.0M shares, about $29.4M), CoreWeave (307,692 shares, about $24.8M) and Venture Global (555,556 shares, about $14.3M).
Over the past 7 days, alphai's AI scored 2 news stories mentioning ADIL (ADIAL PHARMACEUTICALS, INC.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ADIL coverage spans financial news, insider activity and mergers & acquisitions.
This is a routine quarterly financial disclosure via 8-K, but the scraped text does not include the actual financial results or guidance details.
Board and C-suite changes are likely to drive near-term sentiment and volatility, especially given the conditional nature tied to shareholder votes.
The stake increase may support downside stabilization, but it is not a company-issued catalyst.
A disclosed open-market purchase by a large 10% owner signals incremental accumulation, but it is small and indirect, with limited standalone catalyst power.
The filing signals incremental insider/affiliate accumulation, but the disclosed size is modest and indirect, limiting near-term fundamental impact.
alphai scores every news story that mentions ADIL with an AI model for sentiment and relevance, and aggregates insider trades from ADIAL PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001513525 0001513525 2026-08-17 2026-08-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001513525 0001513525 2026-08-10 2026-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readInvesting.com reported U.S. insider trading for July 16, 2026. Major buys included Boundless Bio (63,969 shares, about $155.6k), ADIAL Pharmaceuticals (3,233 shares, $8,690), FIS (1,386 shares, $57.4k) and Cardiff Oncology (34,364 shares plus warrants). Major sells included Celcuity (3.1M shares, about $317.8M), Arista Networks (300k shares, about $54.2M), Butterfly Network (4.0M shares, about $29.4M), CoreWeave (307,692 shares, about $24.8M) and Venture Global (555,556 shares, about $14.3M).
4 min readCoastlands Capital LP purchased 11,753 indirectly-held shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at an average of $2.78 ($2.70–$2.79) across 2 trades over 2026-07-09 to 2026-07-10.
2 min readCoastlands Capital LP purchased 25,000 indirectly-held shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at $2.60 on 2026-06-29.
2 min readAdial Pharmaceuticals said it will acquire Azora Therapeutics and obtain its lead asset AT177 for ulcerative colitis. The deal is paired with a $64 million private placement, including $32 million upfront, issuing pre-funded warrants for 11,780,948 shares at $2.7489. A further $32 million milestone is tied to Phase 1 start. Proceeds will fund AT177 development; proof-of-concept studies are planned for 2027.
4 min readADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029444801ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED JUNE 11, BY AND AMONG ADIAL PHARMACEUTICALS, INC., ADIAL FIRST MERGER SUB, INC., ADIAL SECOND MERGER SUB, LLC AND AZORA THERAPEUTICS, INC Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among: Adi
6 min readAdial Pharmaceuticals is undergoing significant changes, focusing on an upcoming investor presentation and new data in the alcohol use disorder treatment market. The company recently completed a reverse stock split to maintain Nasdaq compliance and filed an international patent application to protect its intellectual property. CEO Cary Claiborne will present clinical advancements and strategic plans at Oppenheimer’s Healthcare Life Sciences Conference, offering investors clarity on the AD04 Phase 3 trial and potential partnerships.
4 min readAdial Pharmaceuticals Inc. (NASDAQ: ADIL) stock fell significantly in after-hours trading after announcing a 1-for-25 reverse stock split scheduled for February 5, 2026. This move is primarily aimed at complying with Nasdaq's minimum bid price requirement of $1.00 per share. The company stated the split will reduce outstanding shares and enhance its capital markets profile for institutional investors.
2 min readGLEN ALLEN, Va., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) ( "Adial" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its ...
2 min read